Essay # 4 in our Book Symposium on Beth Burch’s The Pain Brokers, by W. Bradley Wendel (Cornell)
I am pleased to be part of this review symposium on Beth Burch’s engrossing book, The Pain Brokers. As a mass torts teacher, I am aware that our system of aggregate litigation is at best janky and at worst deeply broken. As a legal ethics scholar and teacher, however, I share Professor Burch’s outrage that the legal profession may be making things worse. In addition to familiar problems like grossly excessive contingency fees (p. 168) and enforcement of arbitration clauses in lawyer-client engagement agreements (p. 216), her story implicates relatively recent developments including alternative business structures and third-party litigation financing. Although I cautiously support both of these developments, what happened to the women profiled in Professor Burch’s book should motivate lawyers and regulators to ensure that adequate safeguards exist to prevent exploitation of vulnerable clients by unscrupulous lawyers.
The three protagonists in the story are Sharon Gore, Jerri Plummer, and Barbara Shepard, each of whom was prescribed a surgical procedure to alleviate urinary incontinence. The procedure involved the implantation of a mesh sling, made by one of several manufacturers of medical devices. The FDA, which had done a fairly cursory pre-market review of pelvic mesh for implantation in women, subsequently warned that the mesh created a greater risk for post-operative complications, including pain, bleeding, and infection, than surgical procedures that did not use mesh (p. 13). A plaintiffs’ tort lawyer would recognize this situation as having the potential for a products liability claim, alleging design defect and failure to warn, against the manufacturer. If the mesh had been used in numerous patients, the claims could be aggregated, increasing the plaintiffs’ leverage against the manufacturer in settlement negotiations. So far, a pretty standard mass tort story.
But here’s the kicker: Mesh remaining in a woman’s body is associated with a risk of future harm. Tort damages generally require some present, manifested harm. Some states allow recovery for the emotional distress experienced by a plaintiff who reasonably fears future harm as a result of exposure to a toxic substance or, in this case, an implanted medical device that may cause complications. Others say, in effect, “wait and see what happens with your risk; if it materializes, you have a claim for damages.” Given the uncertainty of recovery for future damages, the delta in expected recovery between a plaintiff without mesh removal surgery and those who had the mesh removed was $15,000 vs. $230,000. (p.26).
So now imagine, for the sake of argument, a cartoonishly corrupt plaintiffs’ lawyer. How could this lawyer make as much money as possible off pelvic mesh cases? How about hiring an overseas call center that somehow got access to the medical records of millions of people – maybe because it has connections with an insider at a medical-records storage company (p. 23) – and have employees make phone calls to women who had mesh implanted? The operator would know lots of private information about the woman’s surgical procedure, including the date and location of the operation and the physician who performed it. The calls would be terrifying, using language like “ticking time bomb” to refer to the mesh (p. 16). But the operator would offer a solution, a package deal including a flight to Florida, a hotel room and ground transportation to a medical clinic, and a surgical procedure to remove the mesh. The deal would include a lawyer who would then sue the manufacturer on the woman’s behalf for the full amount of damages, including the expense of the removal surgery. From the lawyer’s point of view, cha-ching!
Making this work requires a source of financing, so the lawyer or the marketing company would also have a contract with a funder who would advance the client’s cost for travel and the surgical procedure, in exchange for a share of the proceeds of the eventual recovery from the mesh manufacturer. Alternatively, the lawyer could be partnered up with a non-lawyer investor, as permitted (with guardrails) in Arizona and the District of Columbia. The financing and services would be governed by a thicket of agreements among marketers, financiers, doctors, and lawyers, and as a result it would never be particularly clear who was responsible for providing advice to the plaintiffs, many of whom never met the lawyer they supposedly retained to handle their lawsuit. This diffusion of responsibility would be attractive to unscrupulous players in this market.
The scheme described by Professor Burch is complicated and there are a lot of players in the story. At the risk of oversimplifying, a guy named Blake Barber owned companies called Surgical Assistance and Medical Funding Consultants. The companies were associated with a crooked call-center operator, Vince Chhabra, who had connections with a medical records storage firm in India. Chhabra and his son, along with a guy named Ron Lasorsa, were principals in a D.C. entity called Alpha Law, which was permitted to have non-lawyer investors. Barber’s companies were in the business of factoring medical liens; that is, they purchased unpaid medical bills from surgeons at a discount and obtained a lien on the proceeds of any recovery by the patient/plaintiff. Some of the funding for the women’s travel expenses came from a litigation financing company called LawCash, which made non-recourse investments in the litigation pursued by the women in exchange for a sizeable share of the proceeds. With all these hogs at the trough, the women ended up with next to nothing. For example, when one of the women finally found a good lawyer to solely represent her interests, he had to resolve numerous liens (p. 237):
Barb had borrowed $1,700 to cover food and expenses during her trip to Broward Outpatient. But the loan was for $4,000; Blake’s company, Medical Funding Consultants, received $2,300, and Weintraub tacked on $536 for fees and overnight shipping. Now he wanted $9,072 from Barb.
The book raises a number of powerful critiques of mass tort claim processing, but I will focus on a few interrelated themes: People rely on the tort system as a safety net to correct for regulatory failures like allowing this defective mesh on the market in the first place (pp. 288-89); understandably they expect that the facts and circumstances of their cases will have something to do with the redress they obtain; in fact, however, they receive a kind of mass-produced simulacrum of individualized justice; then, to make things even worse, because of its scale and decentralization, the system is vulnerable to exploitation by a whole panoply of crooks and grifters; thus, what good is produced by aggregate litigation is swamped by the collateral bads created by the greedy actors who take advantage of systemic vulnerabilities.
As a federal district judge put it, at the sentencing of one of the promoters of the scheme (p. 257):
[T]he whole notion that a pile of money is created to compensate people who have been—they are treated with this defective, arguably defective device, and the locusts descend, and I am not leaving out the legal profession here. Lawyers, middlemen, the financers. I mean, it is really a very upsetting picture. It is a very upsetting picture. Almost as if the patients themselves are mere pawns. Afterthoughts.
“Afterthoughts” would have been a good alternative title for the book. While the remainder of this short review will discuss systemic problems with mass tort adjudication, perhaps the most important contribution of Professor Burch’s book is to insist that the individuals caught up in the system never be merely afterthoughts.
1. Individual justice vs. mass processing
This is one of the most familiar themes in mass tort scholarship, and one that Professor Burch is well familiar with, having written some of the leading articles. In the terms made familiar by Richard Nagareda, the arc of mass tort litigation has been from adjudication to administration. Plaintiffs’ lawyers assemble gigantic inventories of cases; scramble for leadership positions on steering and executive committees, sometimes to influence the litigation and help out their clients, but also to become entitled to common benefit fund fees; negotiate with the defendants, who are interested in finality, certainty, and “global peace” above all, and really just want a number they can take to capital markets; and dicker over the design of a claims resolution facility, which will probably employ some type of grid or matrix to set compensation amounts based on certain generic, easily ascertainable factors. Not every MDL looks like that, but it’s been the paradigm for the resolution of most mass litigation since the procedure began to emerge in the 1990s.
The reason for this is well understood, and it’s not a deficiency in Professor Burch’s book that she does not provide the backstory of modern mass tort litigation. Her book is aimed largely at a non-lawyer audience. Lawyers will immediately recognize the source of the problem: In legal-doctrinal terms, most of the cases that get fed into the mass claims processing factory are tort actions, requiring proof of fault and causation, both of which demand extensive fact discovery, medical and scientific experts, and years of motions practice (Daubert and summary judgment being the main hurdles for plaintiffs to overcome) before having a shot at a trial. As Professor Burch notes, regarding an earlier mass tort, “a single case over the heart attack–inducing drug Vioxx (which was billed as a pain reliever) cost lawyers between $1 million and $1.5 million to bring” (p. 30). There’s simply no way for most individual claimants and their lawyers to finance litigation of that sort, which creates almost irresistible pressure toward aggregation. Following the Supreme Court’s Amchem and Ortiz decisions, concluding that the disparities in causation and damages claims made it practically impossible to satisfy the certification requirements of Fed. R. Civ. P. 23(b)(3), plaintiffs’ lawyers latched onto the federal multidistrict litigation (MDL) statute, 28 U.S.C. § 1407, to obtain the economies of scale necessary to finance and prosecute these complex tort claims.
MDLs have their own characteristic failure modes, including the well known “MDL vortex,” which sucks in cases for pretrial litigation but then resists remanding them to the federal district or state court where they originated. Professor Burch alludes to this on pp. 157-58, referring to individual litigation brought by a scrappy young Arkansas lawyer:
Most small-firm lawyers know enough about multidistrict litigation to avoid it. Like a whale that spots a plankton bloom, the MDL inhaled cases like Jerri’s in Arkansas, Barb’s in New Hampshire, and Sharon’s in South Carolina. It sucked them into one huge maw in West Virginia, controlled by a handful of lawyers empowered to speak for women they’d never met. Key facts and evidence could get lost in the mash.
Attorneys like J.R. and Ray would be unable to extricate Jerri’s case from the slurry. And if opposing counsel made an insulting settlement offer, there was no way to threaten to try her case. They’d be stuck. Historically, MDL judges have returned only 1 percent of cases to the place where the suit was originally filed.
The passage refers not only to the MDL vortex but to the agency problems that afflict so many plaintiffs in mass tort litigation: Although in theory all actions in an MDL retain their individuality (unlike a member of a class action), the women in the pelvic mesh MDL in West Virginia were represented “by a handful of lawyers empowered to speak for women they’d never met” – i.e. leadership counsel. The assumption underlying the lawyer-client relationship is that the client sets the agenda and the lawyer communicates with the client about the means by which the client’s objectives are to be pursued (Model Rule 1.2(a)). For plaintiffs represented by lawyers who were not part of the leadership group, however, any meaningful exercise of voice and control over the litigation is largely illusory. The agenda is set by the plaintiffs’ executive committee and all the myriad “means” decisions in connection with claims to be asserted, discovery, motions, choosing bellwether plaintiffs, and the like, are made by lawyers ultimately reporting to the executive committee. As a result, plaintiffs are subjected to mass processing, treated as a file number or a set of exposure and damages criteria to be blended into a settlement package with the defendant.
One of the most important contributions of Professor Burch’s book is to remind all of us who teach or write about mass torts that, hang on, these “inventories” are made up of real people, each with their own story to tell, who have been wronged by the products or services marketed at them in a mass consumer society. The emotional hook comes from viewing mass tort proceedings from the point of view of three women who were initially injured by defective pelvic mesh, but then subjected to additional physical harms and offenses to their dignity by corrupt individuals and a broken system.
From the perspective of the legal system, one of the structuring themes of mass tort litigation is the disjunction between the realities of large-scale claims administration and the expectations of many Americans, raised on generations of lawyer shows on television, of individualized treatment of their claims for redress:
Like most injured people, Barb Shepard and Sharon Gore expected it would be easy to hire a suit-and-tie lawyer who’d investigate their plight and then march into a courtroom to show a jury how a ring of con men had ruined their health on the heels of Big Pharma (p. 211).
The interaction between individual venality and systemic dysfunction is, to my mind, the most interesting intellectual issue raised by the book. But I’m a law professor, so it’s not surprising that I see it that way. For most readers, including the non-lawyer readers who are probably Professor Burch’s primary audience, the overwhelming reaction will likely be outrage that our legal system tolerates a succession of episodes of abuse and exploitation, seemingly without providing any meaningful redress. She writes (p. 266):
What was a woman’s body, a mangled vagina, lifelong incontinence, and the mental toll it all took worth? Could anything really make it right?
The question of whether anything could make a terrible loss right is, of course, present in individual tort cases as well as in aggregate litigation, but the scale and impersonal quality of these proceedings, combined with the loss of individual client voice and control over the handling of the claims by counsel, deepens the sense of alienation from the legal system’s aspiration to justice.
2. Mass tort adjudication downstream of social injustice.
The three women in Professor Burch’s story might never have received defective pelvic mesh implants if regulators at the FDA had done a better job of pre-market approval (compare pp. 13-14). However, this would require increasing the budget of the agency and giving it more power relative to medical device manufacturers, not a politically popular position. When it became apparent that the women were at risk of complications arising from the defective mesh, a decent, publicly funded health care system (as would be familiar to any resident of Canada, the U.K., New Zealand, or . . . oh, I don’t know – any civilized country) would pay for an operation to remove it. There would be no need for the shady network of lien-factoring companies, surgical clinics, PI lawyers, and litigation funders to provide financing for the removal surgery. (Not to mention there would be no financial pressure to perform unnecessary removal surgery.) If we had a publicly funded legal aid system for civil litigants, PI lawyers would not charge contingent fees now approaching a market standard 40% rate, calculated on the gross recovery before deducting expenses, and not taking into account any financing costs incurred by the plaintiffs. Or perhaps there could be a state-funded compensation scheme for people injured by accidents or defective products, comparable to the New Zealand Accident Compensation Commission. Instead, and in the great American tradition of rugged individualism and self-reliance, people injured by the products and services of a mass consumer society are told, KMAGYOYO.[1]
Given individualism, self-reliance, and all that, what should be the role not of the state, but of intermediary institutions, such as the medical and legal profession, in protecting the rights of individuals such as the women in this story? Can we trust doctors not to perform medically unnecessary removal surgeries and lawyers not to advise or allow their clients to enter into ruinously expensive financing arrangements to get medical care they could have obtain otherwise (in several cases mentioned in the book, through private health insurance that would have paid for the surgery)?
This strategy runs into the decades-long decline of trust in professions. To be clear, while the next section will talk mostly about ethical failings by lawyers, the medical profession did not exactly cover itself in glory here either. The urogynecologists who performed the removal surgeries did not appear interested in asking too many questions about how it was that so many women were flying down to a temporary surgical clinic hastily thrown together in an office building. A moment’s thought would have led to the recognition that there must be someone coordinating the flights, hotel stays, and local transportation, so there must be someone locating patients all over the country and funneling them into these surgeries. How were they making money? Was it on the up-and-up? The doctors never seemed to trouble themselves with these questions, and were content to essentially perform assembly-line surgeries.
Professor Burch’s telling of the story highlights the fact that these women were absolutely on their own. One of the lawyers who was supposedly representing the women wrote what was later dubbed the “train wreck” email to the organizers of the scheme (pp. 72-73):
Today was the first time I spoke to each of [the clients]. I was retained by each within the last 48 hours. All three had surgery on 11/22/14; roughly ten (10) days before we were even retained.
This has turned into a total and complete train wreck.
I was told everyone was going to make every effort to have the patients/clients speak with me, Rhett, or any attorney here at our office, before the patients/clients signed the lien, and certainly before surgery.
I have been told several times no more surgeries would occur until the paperwork is complete.
Nothing has changed. In fact, things have worsened.
Now I am expected to sign something stating I, as the person’s attorney, received, reviewed, and explained documents prior to client signing. How is this possible if I am not retained as the person’s attorney until 10 days later?
This is very frustrating and we are all wasting too much time on a problem with an extremely simple solution >>>>>> Do not book flights, hotels and surgeries until an attorney has signed the “attorney acknowledgement.
The three women protagonists met each other in line at a CVS in Florida, waiting to fill prescriptions for pain meds after their surgeries; each of them had been told that they would be provided with a lawyer to sue the manufacturer of the mesh, but none had had any communications with a lawyer up to that point (p. 97). In some cases, the lawyers they had retained, via an electronic signature in a DocuSign packet, were co-counseling with an entity organized under the laws of the District of Columbia, permitting lawyers to practice in association with non-lawyer investors. The women had no idea that they had agreed that the D.C. entity would receive the lion’s share of the attorneys’ fees (p. 167).
A magistrate judge in the West Virginia MDL against the mesh manufacturers described the scheme and expressed her outrage that a lawyer would advise a client to do this (p. 122):
“What I find appalling is that somebody would talk a woman into having a surgery that she might not need, tell her she needed to take a loan out to get it done because her insurance wouldn’t pay for it, and then charge her 30 percent to 50 percent interest a year, which I think is unconscionable. And if that’s happening, I call that unbridled greed. And in my mind that is absolutely unacceptable.
“And it blows my mind,” she finished, “that a lawyer would allow his or her client to get into that sort of situation.”
But, of course, there was no lawyer allowing, or not allowing, a client to do anything. These women were drawn into the scheme without anyone providing them advice or protection.
This leads to the “who will guard the guardians?” problem with respect to the lawyers. For a variety of reasons relating to funding, staffing, and the record-intensive nature of an investigation into this type of misconduct, state bar grievance procedures are not well suited to policing misconduct in mass tort litigation. District courts, however, tend to want to punt the responsibility onto state bar regulators. Here is the district judge in the West Virginia MDL (p. 142):
“I don’t really think the MDL has any connection or any requirement or duty to investigate the Chhabras or Law Firm Headquarters or PRGI,” she said. “If you believe that there’s been fraud committed in some way, you ought to report it to the appropriate agency and allow that agency to conduct an investigation.”
Most of the lawyers profiled in the book, with the exception of Mazin Sbaiti, who kept sending D.C. Bar ethics opinions to his partners (p. 117), did not seem particularly concerned about the possibility of professional discipline. The enforcement gap will remain a catalyst for sleazy behavior in MDLs if the courts supervising these proceedings do not take a more active role in monitoring the compliance of counsel with their professional duties. (A few judges have stepped up, including District Judge M. Casey Rogers in the 3M Combat Arms Earplugs MDL, who ordered disclosure of third-party litigation funding in that proceeding.)
3. The enshittification of mass tort representation – ABSs and TPLF.
The Canadian writer Cory Doctorow coined the term enshittification to describe the process by which a nifty new piece of technology, which initially made things better for users, works great until the owners of the technology figure out a way to make more money by abusing their users, who now have a difficult time disentangling themselves from the technology:
This is enshittification: Surpluses are first directed to users; then, once they’re locked in, surpluses go to suppliers; then once they’re locked in, the surplus is handed to shareholders and the platform becomes a useless pile of shit. From mobile app stores to Steam, from Facebook to Twitter, this is the enshittification lifecycle.
The American civil litigation system is far too decentralized for there to be an equivalent of Amazon or Google to single out for blame, but mass tort litigation is nevertheless somewhere in the middle of the enshittification lifecycle. First there’s something genuinely useful, like consolidation of cases raising “one or more common questions of fact” for pretrial purposes under 28 U.S.C. § 1407. Initially employed in some electrical-equipment antitrust litigation, the MDL statute was repurposed by enterprising plaintiffs’ lawyers to carry the weight of aggregate personal-injury litigation after Amchem and Oritz blew up class actions in the massive pending asbestos proceedings. Plaintiffs and defendants both perceived advantages to having a mechanism under which settlement could be pursued without having to go through the process of certifying a class. The Vioxx litigation marked the beginning of the modern era of MDLs, and it seemed like the advantages of this procedure for handling huge numbers of personal-injury claims would benefit everyone.
The logic of enshittification took over, however, and numerous participants in the system found ways to enrich themselves at the expense of the injured claimants the system was intended to serve. Professor Burch and others have written abouthow repeat players in mass tort adjudication are able to advance their self-interest by exploiting gaps in the rules and lax oversight by courts. Less well understood is the role of various contractors and support services, such as claims administrators, marketing firms, lead generators, claim brokers, and financing firms.
On a simple model, which was formerly used in relatively modest-scale aggregate litigation, a local personal-injury law firm finances a marketing campaign, using print, billboard, radio and TV, and social media advertising to inform people that they may have a claim if they took XYZ prescription drug. Potential plaintiffs call a phone number and a call-center operator forwards their information to a law firm, where a lawyer or, more likely, a paralegal working under the supervision of a lawyer interviews the prospective client to determine whether they have a claim worth pursuing. The firm sends the prospective client an engagement agreement which may include a co-counsel provision under Model Rule 1.5(e), permitting the originating firm to share legal fees with a “handling” firm that will actually work up the case. The handling firm will file the complaint, conduct discovery, deal with pretrial motions, and potentially try the case. In an MDL, the district court will appoint lawyers to a steering committee, liaison counsel, and other leadership roles. In theory at least, there is an agency relationship, running from the client/principal through various lawyer/agents, all of whom owe fiduciary duties to the client:
Client originating law firm handling law firm leadership counsel
It should be apparent how the attenuation of decisionmaking authority and responsibility for communication creates opportunities for firms along the chain to act with diminished loyalty to the ultimate principal, the client.
Each of the law firms may outsource some of the tasks involved in the acquisition and prosecution of claims. In modern mass tort litigation, including the pelvic mesh litigation that is the subject of this book, much of the contact with prospective clients occurs through non-lawyer “lead generating” and claims brokerage companies. Thus, the prospective client may never communicate with a lawyer at the originating law firm. This isn’t suppose to happen. Lawyers contracting with lead-generation services are supposed to have the same level of communication with prospective clients as they would if the client had walked in the office door. In reality, however, mass tort firms may harvest hundreds of signed-up client matters, which are then referred out to handling firms pursuant to co-counsel agreements.
In this book, the mass-production model of aggregate litigation intersects with a relatively recent development in the American legal profession. One is the emergence of alternative business structures (ABS’s) as a form of organization. Most U.S. jurisdictions have adopted a version of ABA Model Rule 5.4, which prohibits lawyers from forming partnerships with nonlawyers or practicing law in the form of any entity in which a nonlawyer owns an interest. The District of Columbia has long been an exception, mostly to accommodate the sort of hybrid law firm/lobbying shops that are not uncommon there. Professor Burch refers to this as a “loophole” (p. 50), but it’s really just a different approach to regulating the delivery of legal services. The D.C. approach, which is now also recognized in Arizona and Puerto Rico, is simply more overt about the profit-making aim of law firms. The objection to the rule is that nonlawyer investors, not subject to the rules of professional conduct, will put a lot of pressure on lawyers to compromise their independent judgment, exercised as fiduciaries for clients. I have to say, however, that plenty of lawyers described in Professor Burch’s book had no trouble chucking their fiduciary duties out the window in the pursuit of greater profits, even without being part of an ABS. This doesn’t mean ABS’s don’t raise concerns, but I’m not as persuaded as Professor Burch that the “faux law firm” Alpha Law (p. 57) was enabled to exploit clients in the way it did simply because it was organized as an ABS under the D.C. rules. Blake Barber, the Chhabrias, and the other sleazy characters who orbited around Alpha Law could have done much the same thing outside of D.C.
The other development that attracts Professor Burch’s critical eye is third-party litigation financing (TPLF). She happened upon a living, breathing metaphor for a dodgy industry in the form of the unkempt general counsel of a consumer litigation funding company (p. 112):
LawCash’s lawyer, who’d soon turn sixty, looked decades older. With a belly that sagged over his belt, he was the kind of man you could picture chomping a cigar in a mustard-stained shirt. When judges criticized the company’s lending practices, calling the interest rates “obviously usurious,” he rushed to split hairs. Those weren’t loans; they were risky advances. “Lenders get paid back with a certainty,” he said. “We don’t know when we give someone a dime if we’ll ever get a penny back.”
Consumer litigation funding – sometimes called pre-settlement financing – is a way for claimants to monetize the value of a future claim, often but not exclusively for personal injury. One of the recurring objections to the industry is that the returns to the financing companies can be exorbitant (p. 238):
“We gave her $4,000 and are owed $9,000, which isn’t a lot for a seven-and-a-half-year investment. Our rates are much higher now,” said Weintraub. “That $4,000 would grow to $35,000.”
It was a glib remark that oozed with snark. J.R.’s blood boiled. He couldn’t believe the guy was joking around about charging personal injury victims like Barb $35,000 for a $1,700 loan.
There is some empirical evidence that most consumer TPLF transactions do not involve anything close to a $35,000 return on a $1,700 investment. This study also finds, however, that many claimants are represented by counsel who are actively involved in negotiating reductions in the return to funders (known as “haircuts”). The women in the story here, however, were mostly unaware that they even had entered into these funding agreements, let alone had diligent counsel capable of negotiating haircuts.
To be clear, I am not arguing that ABSs and TPLF necessarily lead to enshittification. One could just as easily blame excessive contingent fees and lax enforcement of rules prohibiting for-profit lawyer referral services. From what I can tell as an outsider looking in, the lead generating business run amok is as much to blame as anything else. There seems to be a lot of money flowing into non-lawyer business that finance sophisticated mass tort marketing programs on social media – just type “Camp Lejune water” or “talc ovarian cancer” into Google and see what comes up – and the call centers and referral services are mostly unregulated. Under Model Rule 5.3, lawyers who contract with these services are supposed to “make reasonable efforts to ensure that” the contractor’s conduct is compatible with rules of professional conduct, but something tells me that not all plaintiffs’ lawyers, eager to get into the mass tort game, are equally careful with their outside contractors.
* * *
Having thoroughly enjoyed reading the book, and sharing Professor Burch’s outrage at the abuses in the system, I find myself mostly agreeing with her bottom line (pp. 288-89):
Our tort system provides a safety net for millions of Americans who fall prey to products that slip through regulatory cracks. New mass torts proliferate daily, but so, too, do Chhabra-like scams. Earnest plaintiffs’ lawyers like J.R. continue to chip away at injustice, but defusing ticking time bomb tactics requires that each of us has Jerri’s gumption and Barb’s doggedness: Research and question doctors and lawyers. Read the fine print in contracts and health forms. Beware of arbitration clauses. And spread the word.
Reform in this area is difficult, in part because of the observation in #2 above, that many of the problems with the mass tort system are downstream of weak regulation of prescription drugs and medical devices and a grossly inadequate social safety net to provide health care and unemployment compensation as a result of injuries that result from defective products. Given our reliance on neoliberal approaches to ensuring access to legal services, including contingency fees and TPLF, it is hard to resist the relentless process of enshittification. As Cory Doctorow says, “[t]he internet is a must-have, not a nice-to-have, a prerequisite for full participation in employment, education, family life, health, politics, civics, even romance.” Enshittification is enabled when users are locked into a platform.
Our dysfunctional government regulation and thin-to-nonexistent social safety net locks Americans into the tort system for the deterrence of defective products and compensation of the resulting losses. That leaves lawyers, and for the most part their voluntary compliance with ethical norms, as the last line of defense against what happened to Sharon, Jerri, and Barbara. I wish that observation gave me more reason to feel optimistic.
[1] On the authority of Texas songwriter Hayes Carll, I believe this to be an acronym used in the Army, meaning “kiss my ass guys, you’re on your own.” Even if Hayes is making this up (and that’s the kind of thing he would do), it’s a useful expression that perfectly describes the attitude of American society to its less fortunate members.
Like this:
Like Loading...